The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
Using genotype and blood plasma protein information for thousands of healthy individuals, researchers documented variants influencing plasma protein levels.
The parties will use Somalogic's SomaScan platform to investigate the ability of protein measurements to affect patient care in a variety of clinical areas.
The company aims to sell its clinical products not as discrete tests but as sets of "insights" derived from patient proteomic data collected using the platform.
Chinese healthcare firm iCarbonX, which made a $161 million investment in the firm last year, was joined by Nan Fung Life Sciences and Madryn Asset Management.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
The funds come from an equity investment by Chinese health firm iCarbonX announced at the beginning of the year as part of a partnership between the companies.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.